AKT1 and chronic myelogenous leukemia, BCR-ABL1 positive: It is displayed that FAM168A might act as a linker protein binding to BCR-ABL1 and AKT1, further enhanced the activity of AKT1/NF-κB signaling pathway, thus, increased of G2/M phase cells and Cyclin B1 level in chronic myeloid leukemia [23].